| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/06/2005 | US20050004202 Such as 3-[1-(3-methoxypropyl )-1H-indazol-3-yl]-4-[1-(3-pyridinyl )-1H-indol-3-yl]-1H-pyrrole-2,5-dione; protein kinase C and/or glycogen synthase kinase-3 diseases |
| 01/06/2005 | US20050004201 Cardiovascular and inflammatory diseases; immunological, dermatological, oncological and central nervous system disorders; diabetes and associated disorders; protein kinase C and glycogen synthase kinase-3 |
| 01/06/2005 | US20050004200 Pyrazole compounds as integrin receptor antagonists derivatives |
| 01/06/2005 | US20050004199 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| 01/06/2005 | US20050004197 Thrombin receptors antagonists; oral efficacy |
| 01/06/2005 | US20050004194 Use of organic compounds |
| 01/06/2005 | US20050004193 Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases |
| 01/06/2005 | US20050004192 Inhibiting virus's own RNA-dependent RNA polymerase, NS5B |
| 01/06/2005 | US20050004191 Crystallization production of form II; yield, low cost; does not requires rapid cooling |
| 01/06/2005 | US20050004184 Such as 3,5-Dibromo-4-(4-hydroxy-3-phenethylcarbamoyl-phenoxy)-phenyl acetic acid; metabolism regulation agents; avoiding cardiovascular and other toxicities of hormones |
| 01/06/2005 | US20050004183 for preventing, Syndrome X, diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases; peroxisome proliferator activated receptor (PPAR) |
| 01/06/2005 | US20050004182 2-Amino-pyridine derivatives useful for the treatment of diseases |
| 01/06/2005 | US20050004181 Ultilizing combination of doxylamine succinate and pyridoxine hydrochloride |
| 01/06/2005 | US20050004180 Conditions mediated by beta chemokine receptor 2, monocyte chemotactic protein 1 and/or their interaction; such as 4-acetyl-5-cyclohexyl-3-amino-1-(4-methylphenyl)-1,5-dihydro-2H-pyrrol-2-one |
| 01/06/2005 | US20050004179 Improving insulin sensitivity; reducing or inhibiting development of memory impairment |
| 01/06/2005 | US20050004178 Identification and use of lipid metabolism controllers; claimed knockout mouse, isolated EFA-hRUP25 polypeptide, recombinant vector and host cell; dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, type 2 diabetes |
| 01/06/2005 | US20050004177 Joint cartilage damage, inflammation, stiffness, impaired function and/or pain; osteoarthritis, rheumatoid arthritis |
| 01/06/2005 | US20050004176 Pyrazole-amide compounds useful as kinase inhibitors |
| 01/06/2005 | US20050004173 Suppressing expression and/or activity of Carnitin Palmitoyl Transferase-I |
| 01/06/2005 | US20050004172 Solvent free hexacoordinated octahedral form N; acetone solvate forms A3, A4, hexacoordinated octahedral A1 and pentacoordinated square pyramidal A2; methyl acetate solvate forms B2, B3 and hexacoordinated octahedral B1; methylethyl ketone solvate forms C2 and hexacoordinated octahedral C1; desolvated E1 |
| 01/06/2005 | US20050004171 Increasing blood absorption of proton pump inhibitor; adjusting stomach gastric fluid pH with buffering agent to inhibit acid degradation |
| 01/06/2005 | US20050004170 Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage |
| 01/06/2005 | US20050004168 New substituted pyridine or piperidine compounds |
| 01/06/2005 | US20050004167 Such as dibenzofuran-2-carboxylic acid 2-(phenylsulfonyl)hydrazide |
| 01/06/2005 | US20050004166 Imino acid derivatives as inhibitors of matrix metalloproteinases |
| 01/06/2005 | US20050004165 Composition and method for modulating BAR/FXR receptor activity |
| 01/06/2005 | US20050004164 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
| 01/06/2005 | US20050004163 opioid receptor modulators; analgesics, cardiovascular agents and respiratory disease medicants, immunosuppressants, antiinflammatories: reduced side effects |
| 01/06/2005 | US20050004160 Reducing expression of highly proliferate genes; antibacterial and/or antiviral activity; cancer, tumors |
| 01/06/2005 | US20050004158 Achieving hemostasis and preventing fibrous growth after incisions; using such as collagen and rapamycin |
| 01/06/2005 | US20050004155 Use of methylnaltrexone to treat irritable bowel syndrome |
| 01/06/2005 | US20050004154 1,2,8-Triazaspiro{decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders |
| 01/06/2005 | US20050004153 inhibitors of Lymphocyte Function-associated Antigen 1 (LFA-1)/intercellular adhesion molecule (ICAM); use treating transplant rejection, rheumatoid arthritis, diabetes, inflammatory bowel disease, and chronic obstructive pulmonary disease; 2,4-dioxo-1,3,7-triazaspiro[4.4]nonanes |
| 01/06/2005 | US20050004152 Thiazole compounds useful as inhibitors of protein kinase |
| 01/06/2005 | US20050004151 Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators |
| 01/06/2005 | US20050004150 For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders |
| 01/06/2005 | US20050004149 Pyrimidine compound and medicinal composition thereof |
| 01/06/2005 | US20050004148 Human immunodeficiency and hepatitis B infections; high activity, low toxicity |
| 01/06/2005 | US20050004145 KW-3902 (8-(3-noradamantyl)-1,3-dipropylxanthine) as adenosine A1 receptor antagonist combined with at least one other diuretic |
| 01/06/2005 | US20050004144 Broad spectrum, long lasting, nontoxic synthetic immunostimulatory agents; inducing interferon production; inosine monophosphate dehydrogenase (IMPDH); cancer, autoimmune diseases |
| 01/06/2005 | US20050004143 Bi-cyclic pyrimidine inhibitors of TGFbeta |
| 01/06/2005 | US20050004142 furo(2,3-d)pyrimidine and thieno(2,3-d)pyrimidine compounds for treating cancer and hyperproliferative diseases; receptor tyrosine kinase inhibitors |
| 01/06/2005 | US20050004140 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states |
| 01/06/2005 | US20050004139 Pharmaceutical preparations containing aminobenzene-sulfonic acid derivatives as the active ingredient |
| 01/06/2005 | US20050004138 Overcoming phobias |
| 01/06/2005 | US20050004137 Utilizing ziprasidone, derivative or related compound |
| 01/06/2005 | US20050004136 Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful as neurokinin receptor modulators |
| 01/06/2005 | US20050004135 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 01/06/2005 | US20050004134 Adenosine antagonists; having 6-oxo-1,6-dihydro-3-pynidazinyl functionality; synthesis |
| 01/06/2005 | US20050004133 Inhibiting ligand gated ion channel vanilloid receptor (VR1); pain relievers; such as 6-(3,4-dichloro-phenyl)-N-(2-oxo-2,3-dihydro-1H-benzoimidazol-5-yl)-nicotinamide |
| 01/06/2005 | US20050004132 Pain, immune diseases, inflammatory disorders; low toxicity; such as 1-[2-(3-(4-Pyridyl)phenyl)ethyl]-4-(3-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine 1-oxide |
| 01/06/2005 | US20050004130 New metabotropic glutamate receptor compounds |
| 01/06/2005 | US20050004129 Pyrazole derivatives |
| 01/06/2005 | US20050004128 4-(6-chloro-, methyl- or thien-3-yl-oxazolo[4,5-b]pyrid-2-yl)-1,4-diazabicyclo[3.2.2]nonane or salts; nicotinic receptor associated disorders; cholinergic agents |
| 01/06/2005 | US20050004127 Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone |
| 01/06/2005 | US20050004126 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors |
| 01/06/2005 | US20050004125 Such as 4-[[4-(1-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]-benzonitrile; bipolar disorder, pain, type 2 diabetes |
| 01/06/2005 | US20050004124 Synergistic mixture; antidiabetic agents; antiischemic agents |
| 01/06/2005 | US20050004120 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents |
| 01/06/2005 | US20050004119 Trypsin like serine protease enzyme inhibitors |
| 01/06/2005 | US20050004117 Such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile; type 2 diabetes mellitus, diabetic dislipidemia, impaired glucose tolerance |
| 01/06/2005 | US20050004116 Triazole inhibitors of type 2 methionine aminopeptidase |
| 01/06/2005 | US20050004115 such as 4-(4-(2-Fluorobenzyloxy)phenyl)-4-oxobutyric acid; for treatment of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis |
| 01/06/2005 | US20050004112 C-fms kinase inhibitors |
| 01/06/2005 | US20050004110 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 01/06/2005 | US20050004109 Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia |
| 01/06/2005 | US20050004108 Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degenaration |
| 01/06/2005 | US20050004107 Telmisartan sodium salt pharmaceutical formulation |
| 01/06/2005 | US20050004106 Therapy for drug resistant disease; anxiolytic agents; psychological disorders |
| 01/06/2005 | US20050004105 Using serotonine receptor antagonist |
| 01/06/2005 | US20050004104 Methods for the protection of memory and cognition |
| 01/06/2005 | US20050004102 Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain |
| 01/06/2005 | US20050004101 Therapy for schizophrenia, obsessive complusive disorders; antidepressants; anxiolytic agents; panic disorders; antiepileptic agents; analgesics; headaches; sleep disorders; eating disorders |
| 01/06/2005 | US20050004099 Spiroazabicyclic heterocyclic compounds |
| 01/06/2005 | US20050004098 Administering formulation comprising an anti-inflammatory agent to the organ via the exterior orifice |
| 01/06/2005 | US20050004097 Indole derivatives |
| 01/06/2005 | US20050004096 Indole derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 01/06/2005 | US20050004095 Carbacephem beta-lactam antibiotics |
| 01/06/2005 | US20050004093 Using 6-betahydroxymethylpenicillanic acid sulfone; bactericides; therapy for bacteria infections in mammals |
| 01/06/2005 | US20050004091 Biologically active complex |
| 01/06/2005 | US20050004090 Novel estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors |
| 01/06/2005 | US20050004089 Nitrate esters of corticoid compounds and pharmaceutical applications thereof |
| 01/06/2005 | US20050004088 Hormonal contraceptive product |
| 01/06/2005 | US20050004087 Methods and compositions for treating an ocular neovascular disease |
| 01/06/2005 | US20050004084 Aspirin-containing trasdermal pharmaceutical composition for the treatment of calcification |
| 01/06/2005 | US20050004082 Ether compounds |
| 01/06/2005 | US20050004081 Pharmaceutical combinations for the treatment of cancer |
| 01/06/2005 | US20050004080 Brain disorders; antiischemic agents; antiepileptic agents; cardiovascular disorders; vision defects; spinal cord injuries; psychological disorders; anxiolytic agents; schizophrenia |
| 01/06/2005 | US20050004079 Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof |
| 01/06/2005 | US20050004078 Nucleotide analogs with six-membered rings |
| 01/06/2005 | US20050004077 Antidiabetic agents ; bioavailability |
| 01/06/2005 | US20050004076 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof |
| 01/06/2005 | US20050004074 Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| 01/06/2005 | US20050004073 Pharmaceutical composition comprising chito-oligomers |
| 01/06/2005 | US20050004071 Using sulfated polysaccharides ; therapy for severe acute repiratory syndrome |
| 01/06/2005 | US20050004070 Anti-infectious carbohydrates |
| 01/06/2005 | US20050004068 Modulation of tor |
| 01/06/2005 | US20050004062 Immunostimulatory oligonucleotides; activation lymphocytes; antibody therapy; anticancer agents |
| 01/06/2005 | US20050004061 Immunostimulatory nucleic acid molecules |
| 01/06/2005 | US20050004057 Antiinflammatory agents; dietetics; cosmetics |